BJU Int. 2000 Sep;86(4):466-8.

Extracorporeal shock wave therapy in the management of Peyronie’s disease: initial experience.

Husain JLynn NNJones DKCollins GNO’Reilly PH.

Source

Department of Urology, Stepping Hill Hospital, Stockport, UK.

Abstract

OBJECTIVE:

To evaluate prospectively the efficacy of extracorporeal shock wave therapy (ESWT) as a conservative treatment for Peyronie’s disease.

PATIENTS AND METHODS:

After obtaining ethical committee approval, 37 patients with Peyronie’s disease were treated using ESWT. Beforetreatment the degree of angulation was assessed by artificially inducing an erection with a vacuum device. The severity of pain on erection was assessed using a visual analogue scale (0-5). Each patient was treated with a minimum of three sessions of ESWT (3000 shock waves at an energy density of 0.11-0.17 mJ/mm2) at 3-week intervals. The results were analysed using the Wilcoxon signed-rank test.

RESULTS:

Of the 37 patients, 34 completed the protocol; the mean (range) duration of the disease was 19.43 (4-60) months and the mean follow-up 7.5 (5-11) months. Almost half (47%) of the patients reported an improvement in angulation, with a mean reduction of 29.3 degrees (10 degrees -60 degrees ) (P < 0.001); 12 of the 20 (60%) patients with pain on erection reported immediate relief, the mean reduction being 2.3 (1-4) on the visual analogue scale (P < 0.001). There was only minimal bruising at the site of treatment and no major side-effects were reported.

CONCLUSION:

ESWT is an effective and safe treatment for Peyronie’s disease; the long-term follow-up and results are awaited.

PMID:

 

10971273

 

[PubMed – indexed for MEDLINE]